(Reuters) -Pfizer lifted its annual profit forecast, banking on cost cuts, a smaller-than-feared drop in sales for its COVID antiviral treatment and strong demand for pneumonia vaccine, sending its shares up about 2% before the bell on Wednesday. Shares of the U.S. drugmaker have lost 11% of their value this year on worries over its […]
(Reuters) -Pfizer lifted its annual profit forecast on Wednesday, banking on cost cuts and better-than-expected demand for its COVID antiviral treatment and vaccine. The U.S. drugmaker’s shares rose nearly 3% before the bell after the company said it expects adjusted earnings per share of $2.15 to $2.35 in 2024 compared with a prior forecast of […]
By Sam Tobin LONDON (Reuters) – Pfizer and BioNTech asked a London court to revoke rival Moderna’s patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global legal battle began on Tuesday. Pfizer and its German partner BioNTech sued Moderna at London’s High Court in September 2022, […]
If you had bought $1,000 worth of Pfizer (NYSE: PFE) shares five years ago, how much would that be worth today? The answer will strike you as terrific or terrible: $840. That answer will be terrible if you did buy into Pfizer then as it reflects a loss, not a gain — of about 16% […]
Dive Brief: Uwe Schoenbeck, a biotech veteran who most recently was chief scientific officer at Pfizer’s innovation division, has joined Canaan Partners as a venture partner, the investment firm announced Wednesday. Since starting at Canaan in January, Schoenbeck has led Canaan’s involvement in a $132 million Series B round for precision cancer drug developer Alterome […]
Pfizer (NYSE: PFE) isn’t exactly a hot stock right now. Since its massive run-up during the pandemic’s height, built on hopes for its coronavirus vaccine, new sources of growth haven’t led to equally outsized windfalls. But for investors, it could still be a great pickup once a few of the loftier expectations about its future […]
Pfizer (NYSE: PFE) stock is relatively cheap. I can easily back up that claim. The big drugmaker’s shares trade at lower forward earnings multiples than the S&P 500 and the S&P 500 healthcare sector. That meets the definition of relatively cheap. However, I wouldn’t go so far as to claim that Pfizer is the cheapest […]
Pfizer (NYSE: PFE) stock has been struggling for a while now. In the past 12 months, it has declined by 36%. A lack of growth recently, a dependence on acquisitions, and many question marks have resulted in a lot of investors simply taking a pass on this top healthcare stock. But could that be a […]
A few years ago, both Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) were flying high: from an earnings and share performance perspective. They each sold a leading coronavirus vaccine — and Pfizer sold a COVID treatment too — and these products generated billions of dollars in earnings for the companies. Pfizer and Moderna still sell […]
One of the biggest tailwinds in the pharmaceutical industry is weight loss treatments. Breakthroughs in semaglutide and tirzepatide have given rise to several glucagon-like peptide-1 (GLP-1) medications, including Ozempic, Rybelsus, Wegovy, Mounjaro, and Zepbound. While that is a long list of treatments, only two companies are the brains behind these blockbuster drugs: Novo Nordisk and […]
Some investors look at Pfizer (NYSE: PFE) as a has-been. That’s understandable in some ways. Sales for the company’s once-formidable COVID-19 franchise have tanked. So have Pfizer’s overall revenue, profits, and share price. However, there’s an argument that Pfizer is more of a “will-be” than a has-been. Could the drugmaker even be a trillion-dollar stock […]
If a dividend stock is struggling and falling in value, that pushes its yield up. This happens because while you are getting the same dividend, it is now costing you less money to acquire it. As long as the dividend remains sustainable, buying a dividend stock on a dip in price or near a low […]